Clinical Study Protocol for Ultra-transplantation for the Treatment of Eastern Mediterranean Major
Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.
• Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types;
• Age between 7-12 years old, male or female not limited; Weight\<40kg
• The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo gene therapy for thalassemia;
• There are HLA matched or mismatched donors who meet the donor criteria through physical examination;
• The patient and their family agree to receive super transplantation treatment and sign a written informed consent form before the transplantation trial.